Effect of Lurasidone on Social Functioning in Schizophrenia

Miura, Itaru; Sano, Fumiya; Sakaguchi, Reiko; Okamoto, Keisuke; Maruyama, Hidenori

doi:10.4088/jcp.23m14881

Cited by 1 publication

(1 citation statement)

References 36 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study, however, indicates that impairments in cognitive function in schizophrenia correlate strongly with assessments of “life activities – household”, “participation in society”, and “getting along with people”, all dimensions that overlap with the concept of “life engagement”. 31 Lurasidone has been found to improve cognitive function, 32 , 33 social cognition, 34 and social function, 35 in patients with schizophrenia. Thus, it is possible that lurasidone improves life engagement through the improvement of cognitive function, social cognition and/or social function.…”

Section: Discussionmentioning

confidence: 99%

Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study

Maruyama,

Sano,

Sakaguchi

et al. 2024

NDT

Self Cite

View full text Add to dashboard Cite

Purpose To evaluate the effect of lurasidone on a new, patient Life Engagement scale in schizophrenia. Patients and Methods This post-hoc analysis included participants (ages 18 to 74) diagnosed with schizophrenia who were randomized to lurasidone (40 mg/day) or placebo in a 6-week double-blind efficacy study and those who continued in a subsequent 12-week open-label extension study during which patients received either 40 or 80/mg day lurasidone (flexibly dosed). Change in life engagement was measured using the Positive and Negative Syndrome Scale (PANSS) 11-item Life Engagement subscale score, and individual subscale items, at week 6 during the double-blind phase and extension phase week 12 during the open-label extension phase. Results Analysis focused on 478 subjects randomized to lurasidone or placebo during the 6-week trial, and 146 who received lurasidone during the extension phase. During the 6-week trial, there was a significantly greater change on the PANSS 11 Life Engagement subscale score from baseline to week 6 in the lurasidone group compared to the placebo group (mean changes of −6.4 and −4.8, respectively, p = 0.006; effect size = 0.27). Further improvement was evident during the extension phase for patients who received lurasidone in both phases, with a mean change from double-blind baseline to week 12 of the open-label treatment phase of −10.1 on in PANSS 11 Life Engagement subscale. Conclusion This post-hoc analysis suggests that lurasidone may improve life engagement in patients with schizophrenia, a meaningful outcome from patients’ perspective. Further studies are needed to confirm this effect. Eudract Number Trial registration: EudraCT Numbers: 2016-000060-42; 2016-000061-23.

show abstract